08.05.2018
Evotec AG DE0005664809
DGAP-News: EVOTEC AND CARNA BIOSCIENCES COLLABORATE ON INDIGO PLATFORM
DGAP-News: Evotec AG / Key word(s): Miscellaneous
EVOTEC AND CARNA BIOSCIENCES COLLABORATE ON INDIGO PLATFORM
08.05.2018 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
* EVOTEC LEVERAGES INDIGO PLATFORM TO ACCELERATE THE DEVELOPMENT OF
CARNA'S PROGRAMME CB-1763 THROUGH TO IND FILING
* IND-FILING ENVISAGED FOR FIRST HALF OF 2019
* INDIGO, A KEY VALUE-DRIVING COMPONENT OF EVOTEC'S EVT EXECUTE BUSINESS
SEGMENT, ACCELERATES EARLY DRUG CANDIDATES INTO THE CLINIC BY REDUCING
TIME FROM NOMINATION TO REGULATORY SUBMISSION
Hamburg, Germany, 08 May 2018:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today
announced a strategic collaboration with Carna Biosciences, Incorporated
("Carna"). Carna will access Evotec's INDiGO platform to accelerate the
development of its programme CB-1763, which is being developed for the
treatment of blood cancer, through to the submission of an Investigational
New Drug Application ("IND") with the U.S. Food and Drug Administration.
"We are excited to initiate IND-enabling studies for our next-generation
non-covalent BTK inhibitor, CB-1763, in collaboration with Evotec", said Dr
Masaaki Sawa, Chief Scientific Officer at Carna Biosciences. "We've been
working with Evotec from last year and found they are a really reliable
partner. We believe Evotec's INDiGO programme and their team will help us to
accelerate the development of our CB-1763 and we are confident that we will
achieve our goal to reach IND-filing in the first half of 2019."
Dr Mario Polywka, Chief Operating Officer of Evotec, added: "This
development of Carna's key project directly reflects the success of our
comprehensive and industry-unique INDiGO service. We are delighted to
support Carna's CB-1763 inhibitor programme, an innovative approach to blood
cancer, through to the clinic. Additionally, working with Carna also
highlights our increasing presence in the Japanese market."
Carna has another reversible BTK inhibitor in pre-clinical development,
AS-871, a novel non-covalent BTK inhibitor targeting autoimmune diseases.
AS-871 is also undergoing IND-enabling studies in collaboration with Evotec.
About Evotec's INDiGO platform
The INDiGO platform is a key value-generating component of Evotec's broad
EVT Execute business segment. INDiGO accelerates early drug candidates into
the clinic by reducing time from nomination to regulatory submission in 52
weeks, and under circumstances, even less. We achieve accelerated
development by tightly integrating traditional drug silos into a single
project managed under one roof. The programme has been proven to reduce time
and cost while achieving a quality data package for CTA/IND level regulatory
filings.
Evotec's INDiGO projects are managed by our most experienced, dedicated
project managers and leading world-class drug development professionals
implementing tailored development strategies designed specifically for the
molecule, therapeutic area and strategic needs. The project plan is designed
to integrate development areas: API Manufacture, Formulation Development,
Clinical Supply, Safety Assessment, DMPK, Bioanalysis Studies and Regulatory
Submission Documents Preparation.
ABOUT CARNA BIOSCIENCES, INC.
Carna Biosciences is a biopharmaceutical company focused on the discovery
and development of kinase inhibitor drugs to address serious unmet medical
needs. Carna has intensively focused its research efforts primarily in the
areas of oncology and autoimmune/inflammation, where the company believes
its extensive expertise in kinases can be most effectively leveraged. Taking
advantage of Carna's proprietary platform technologies and highly focused
kinase expertise, the company continues to challenge to identify and develop
innovative drugs. Carna is a publicly traded company in the JASDAQ of the
Tokyo Stock Exchange with securities code 4572. For more information, please
visit www.carnabio.com.
ABOUT CB-1763
CB-1763 is a highly selective, orally bioavailable, non-covalent inhibitor
of Bruton's tyrosine kinase (BTK) with a potential application in the
treatment of blood cancer. Recent studies have indicated that the emergence
of BTK mutations causes ibrutinib resistance. A selective and non-covalent
BTK inhibitor is therefore highly demanded to overcome the emerging unmet
medical need of ibrutinib resistance. CB-1763 is a next-generation
non-covalent BTK inhibitor, designed to inhibit both BTK wild type and BTK
C481 mutants in a highly selective and reversible manner.
MEDIA CONTACT:
CORPORATE PLANNING
CARNA BIOSCIENCES, INC.
TEL: +81-78-302-7075
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 80 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with e.g. with Sanofi in the field of diabetes,
with Pfizer in the field of tissue fibrosis and Celgene in the field of
neurodegenerative diseases. For additional information, please go to
www.evotec.com and follow us on Twitter @EvotecAG.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking statements
are neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
08.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard);
Regulated Unofficial Market in Dusseldorf, Hamburg,
Hanover, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
683359 08.05.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT